Exicure (XCUR) Amortization of Deferred Charges (2016 - 2026)
Exicure's (XCUR) quarterly Amortization of Deferred Charges came in at $57000.0 in Q1 2026, up 21.28% YoY from $47000.0 in Q1 2025, and down 55.81% on a QoQ basis from $129000.0 in Q4 2025.
Exicure (XCUR) Amortization of Deferred Charges (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Amortization of Deferred Charges data on file, last reported at $57000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 21.28% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $228000.0 (down 64.87% YoY) and the FY2025 annual result came in at $218000.0, down 72.61% from the prior year.
- Amortization of Deferred Charges declined to $57000.0 in Q1 2026, from $129000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $205000.0 in Q4 2024 to a low of -$39000.0 in Q4 2022.
- A 5-year average of $134647.1 and a median of $175000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges tumbled 154.93% — and 2023, when it jumped 587.18%.
- Tracing XCUR's Amortization of Deferred Charges over 5 years: stood at -$39000.0 in 2022, then jumped by 587.18% to $190000.0 in 2023, then increased by 7.89% to $205000.0 in 2024, then sank by 37.07% to $129000.0 in 2025, then slumped by 55.81% to $57000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $57000.0 (Q1 2026), $129000.0 (Q4 2025), and -$15000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | -15,000.00 |
| Sep 30, 2025 | -15,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 205,000.00 |
| Dec 31, 2024 | 205,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 194,000.00 |
| Mar 31, 2024 | 194,000.00 |
| Dec 31, 2023 | 190,000.00 |
| Dec 31, 2023 | 190,000.00 |